Table 3. Prevalence of PIM according to Beers (B) and PROMPT (P) criteria 2012-2016, stratified by age Table 3. Prevalence of PIM according to Beers (B) and PROMPT (P) criteria 2012-2016, stratified by age Table 3. Prevalence of PIM according to Beers (B) and PROMPT (P) criteria 2012-2016, stratified by age Table 3. Prevalence of PIM according to Beers (B) and PROMPT (P) criteria 2012-2016, stratified by age Table 3. Prevalence of PIM according to Beers (B) and PROMPT (P) criteria 2012-2016, stratified by age Table 3. Prevalence of PIM according to Beers (B) and PROMPT (P) criteria 2012-2016, stratified by age Table 3. Prevalence of PIM according to Beers (B) and PROMPT (P) criteria 2012-2016, stratified by age Table 3. Prevalence of PIM according to Beers (B) and PROMPT (P) criteria 2012-2016, stratified by age Table 3. Prevalence of PIM according to Beers (B) and PROMPT (P) criteria 2012-2016, stratified by age Table 3. Prevalence of PIM according to Beers (B) and PROMPT (P) criteria 2012-2016, stratified by age Table 3. Prevalence of PIM according to Beers (B) and PROMPT (P) criteria 2012-2016, stratified by age
Year 2012 2012 2013 2013 2014 2014 2015 2015 2016 2016
PIM Identification Age 45-64 Age ≥ 65 Age 45-64 Age ≥ 65 Age 45-64 Age ≥ 65 Age 45-64 Age ≥ 65 Age 45-64 Age ≥ 65
Antihistamines, first generation (B) x 1.74 x 1.69 x 1.45 x 1.48 x 1.34
Antihistamines, first generation as first-line (P) 0.16 0.01 0.12 0.03 0.18 0.00 0.1 0.01 0.23 0.02
Corticosteroids long-term without bisphosphonate (P) 2.30 3.11 2.53 3.01 2.64 2.87 2.53 2.97 2.63 2.45
Tricyclic antidepressants (B) x 5.93 x 6.09 x 6.08 x 6.32 x 6.52
Tricyclic antidepressants as first-line (P) 0.16 x 0.12 x 0.18 x 0.1 x 0.23 x
Benzodiazepines (B) x 10.59 x 10.28 x 9.83 x 8.95 x 8.85
Benzodiazepines long-term (P) 11.36 10.34 11.25 10.24 10.71 9.85 10.88 9.71 10.97 9.35
Nonbenzodiazepines (B) x 2.22 x 2.24 x 2.24 x 2.22 x 2.21
Nonbenzodiazepines long-term (P) 2.02 2.00 1.79 2.05 1.86 2.00 2.02 1.96 2.24 2.02
Strong opioid without laxatives (P) 9.36 7.36 9.11 7.60 9.69 8.22 10.37 8.22 9.96 8.26
Sulfonylureas, long-acting (B, P) 0.46 0.99 0.43 0.72 0.35 0.53 0.25 0.44 0.23 0.31
PPI long-term high-dose (P) 22.62 x 23.92 x 24.12 x 23.79 x 23.31 x
PPI long-term high-dose, except with NSAID or corticosteroid (P adapted) x 17.23 x 17.6 x 17.78 x 17.70 x 17.72
Stimulant laxative no long-term, except with opioid (P) 0.50 0.56 0.49 0.52 0.45 0.48 0.45 0.4 0.35 0.47
NSAIDs long-term without PPI or misoprostol (P) 3.48 x 3.96 x 3.63 x 3.23 x 3.05 x
NSAIDs without PPI or misoprostol (B) x 1.2 x 0.86 x 0.96 x 0.82 x 0.81
Dipyridamole monotherapy (P) 0.28 x 0.19 x 0.43 x 0.33 x 0.12 x
Dipyridamole (B) x 5.18 x 5.58 x 5.66 x 5.12 x 4.37
Theophylline monotherapy (P) 0.04 0.01 0.08 0.01 0.04 0.03 0.00 0.00 0.00 0.00
Acetylsalicylic acid >150 mg/day (P) 0.06 0.3 0.08 0.22 0.25 0.36 0.02 0.09 0.07 0.09
Skeletal muscle relaxants (B) x 0.3 x 0.26 x 0.27 x 0.31 x 0.33
Antispasmodics, anticholinergic (B) x 1.16 x 1.15 x 1.09 x 1.06 x 0.99
Estrogen (B) x 0.18 x 0.16 x 0.14 x 0.14 x 0.1
Insulin sliding scale (B) x 1.71 x 1.58 x 1.61 x 1.79 x 1.86
Disopyramide (B) x 0.028 x 0.026 x 0.026 x 0.026 x 0.03
Indomethacin (B) x 0.07 x 0.07 x 0.07 x 0.09 x 0.08
Digoxin high-dose (B) x 1.36 x 1.19 x 1.08 x 1.00 x 0.92
Nifedipine, immediate release (B) x 0.07 x 0.05 x 0.07 x 0.06 x 0.05
Pentazocine (B) x 0.02 x 0.02 x 0 x 0 x 0
B: Beers criteria P: PROMPT criteria Barbiturates, Meprobamate, Ergoloid mesylates, Desiccated thyroid, Megestrol, Mineral oil, Meperidine, and Ketorolac were not dispensed in study period B: Beers criteria P: PROMPT criteria Barbiturates, Meprobamate, Ergoloid mesylates, Desiccated thyroid, Megestrol, Mineral oil, Meperidine, and Ketorolac were not dispensed in study period B: Beers criteria P: PROMPT criteria Barbiturates, Meprobamate, Ergoloid mesylates, Desiccated thyroid, Megestrol, Mineral oil, Meperidine, and Ketorolac were not dispensed in study period B: Beers criteria P: PROMPT criteria Barbiturates, Meprobamate, Ergoloid mesylates, Desiccated thyroid, Megestrol, Mineral oil, Meperidine, and Ketorolac were not dispensed in study period B: Beers criteria P: PROMPT criteria Barbiturates, Meprobamate, Ergoloid mesylates, Desiccated thyroid, Megestrol, Mineral oil, Meperidine, and Ketorolac were not dispensed in study period B: Beers criteria P: PROMPT criteria Barbiturates, Meprobamate, Ergoloid mesylates, Desiccated thyroid, Megestrol, Mineral oil, Meperidine, and Ketorolac were not dispensed in study period B: Beers criteria P: PROMPT criteria Barbiturates, Meprobamate, Ergoloid mesylates, Desiccated thyroid, Megestrol, Mineral oil, Meperidine, and Ketorolac were not dispensed in study period B: Beers criteria P: PROMPT criteria Barbiturates, Meprobamate, Ergoloid mesylates, Desiccated thyroid, Megestrol, Mineral oil, Meperidine, and Ketorolac were not dispensed in study period B: Beers criteria P: PROMPT criteria Barbiturates, Meprobamate, Ergoloid mesylates, Desiccated thyroid, Megestrol, Mineral oil, Meperidine, and Ketorolac were not dispensed in study period B: Beers criteria P: PROMPT criteria Barbiturates, Meprobamate, Ergoloid mesylates, Desiccated thyroid, Megestrol, Mineral oil, Meperidine, and Ketorolac were not dispensed in study period B: Beers criteria P: PROMPT criteria Barbiturates, Meprobamate, Ergoloid mesylates, Desiccated thyroid, Megestrol, Mineral oil, Meperidine, and Ketorolac were not dispensed in study period